OncoMatch/Clinical Trials/NCT07242547
Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
Is NCT07242547 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tarlatamab for limited-stage small-cell lung cancer.
Treatment: Tarlatamab — This is an open-label, phase II, exploratory and multi-centre clinical trial. 37 Limited stage SCLC patients not eligible for concurrent chemo-radiotherapy will be enroll. Patients will be enrolled in the trial after receiving sequential chemo-radiotherapy, if there is no progression disease, patients will be treated with maintenance Tarlatamab. Patients will receive maintenance with Tarlatamab IV until disease progression unacceptable toxicity, patient or physician decision to discontinue or death. The primary objective is to evaluate the Progression free survival (PFS). Patient accrual is expected to be completed within 2 years. Treatment and follow-up are expected to extend the study duration to a total of 5 years. Patients will be followed for 2 years after enrollment. The study will end once survival follow-up has concluded.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Disease stage
Required: Stage III
Excluded: Stage IV
Limited Stage SCLC; Extensive-stage SCLC (ES-SCLC) or any previous diagnosis of transformed non-small cell lung cancer. Mixed tumors (SCLC-NSCLC) are not eligible.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemotherapy — sequential chemo-radiotherapy or chemotherapy alone
Patients who: 1. were treated with sequential chemo-radiotherapy 2. were treated only with chemotherapy
Lab requirements
Blood counts
adequate organ function (hematological and biochemistry parameters)
Cardiac function
no clinically significant electrocardiogram (ecg) findings; myocardial infarction and/or symptomatic congestive heart failure (new york heart association >class ii) within 6 months prior to first dose of study treatment [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify